Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

2.

Oncogenic activation of androgen receptor.

Kung HJ, Evans CP.

Urol Oncol. 2009 Jan-Feb;27(1):48-52. doi: 10.1016/j.urolonc.2008.06.002. Review.

3.

Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.

Gelman IH.

Int J Biol Sci. 2014 Jun 5;10(6):620-6. doi: 10.7150/ijbs.8264. eCollection 2014. Review.

4.

Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.

Mahajan K, Mahajan NP.

J Cell Physiol. 2010 Aug;224(2):327-33. doi: 10.1002/jcp.22162. Review.

5.

Targeting tyrosine kinases and autophagy in prostate cancer.

Kung HJ.

Horm Cancer. 2011 Feb;2(1):38-46. doi: 10.1007/s12672-010-0053-3. Epub 2010 Dec 2. Review.

6.

ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.

Mahajan K, Mahajan NP.

Oncogene. 2015 Aug 6;34(32):4162-7. doi: 10.1038/onc.2014.350. Epub 2014 Oct 27. Review.

7.

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Araujo J, Logothetis C.

Cancer Treat Rev. 2010 Oct;36(6):492-500. doi: 10.1016/j.ctrv.2010.02.015. Epub 2010 Mar 11. Review.

8.

ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Mahajan K, Mahajan NP.

Cancer Lett. 2013 Sep 28;338(2):185-92. doi: 10.1016/j.canlet.2013.04.004. Epub 2013 Apr 15. Review.

9.

AR, the cell cycle, and prostate cancer.

Balk SP, Knudsen KE.

Nucl Recept Signal. 2008 Feb 1;6:e001. doi: 10.1621/nrs.06001. Review.

10.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

11.

Src signaling pathways in prostate cancer.

Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606. doi: 10.1007/s10555-013-9481-1. Review.

12.

Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors.

Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnerta H, Ungefroren H.

Anticancer Agents Med Chem. 2017;17(10):1351-1356. doi: 10.2174/1871520617666170103094946. Review.

PMID:
28044939
13.

[SRC kinases in tumor therapy].

Dempke W, Zippel R.

Med Klin (Munich). 2010 Oct;105(10):711-5. doi: 10.1007/s00063-010-1123-y. Epub 2010 Oct 28. Review. German.

PMID:
20981590
14.

Signaling inhibitors in the treatment of prostate cancer.

Hudes GR.

Invest New Drugs. 2002 May;20(2):159-72. Review.

PMID:
12099576
15.

Activation of the androgen receptor by polypeptide growth factors and cellular regulators.

Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, Klocker H.

World J Urol. 1995;13(5):285-9. Review.

PMID:
8580999
16.

Clinical development of SRC tyrosine kinase inhibitors in lung cancer.

Lee D, Gautschi O.

Clin Lung Cancer. 2006 May;7(6):381-4. Review.

PMID:
16800962
17.

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Ahluwalia MS, de Groot J, Liu WM, Gladson CL.

Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014. Review.

18.

Extranuclear partners of androgen receptor: at the crossroads of proliferation, migration, and neuritogenesis.

Castoria G, Auricchio F, Migliaccio A.

FASEB J. 2017 Apr;31(4):1289-1300. doi: 10.1096/fj.201601047R. Epub 2016 Dec 28. Review.

PMID:
28031322
19.

Androgen receptor phosphorylation: biological context and functional consequences.

Koryakina Y, Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Aug;21(4):T131-45. doi: 10.1530/ERC-13-0472. Epub 2014 Jan 14. Review.

20.

Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

de Groot J, Milano V.

J Neurooncol. 2009 Nov;95(2):151-163. doi: 10.1007/s11060-009-9916-2. Epub 2009 May 13. Review.

PMID:
19436954

Supplemental Content

Support Center